Hexarelin Peptide Reduces Atherosclerosis by Blocking Macrophage Cholesterol Uptake
Background
Atherosclerosis is a progressive inflammatory disease characterized by the buildup of fatty plaques in artery walls, leading to serious cardiovascular complications. A critical step in plaque formation involves macrophages taking up oxidized low-density lipoprotein (ox-LDL), which contributes to foam cell formation and inflammation. This study investigated whether the growth hormone secretagogue Hexarelin could attenuate atherosclerosis by specifically targeting the LOX-1-NF-κB signaling pathway involved in macrophage ox-LDL uptake.
Results
The study found that Hexarelin treatment significantly reduced the progression of atherosclerosis in the ApoE-/- mice. > The group treated with 1.0 mg/kg Hexarelin exhibited a remarkable 43% reduction in atherosclerotic plaque area in the aorta compared to the control group (p<0.001). Furthermore, Hexarelin significantly suppressed macrophage infiltration into the plaques, showing a 35% decrease in macrophage content. Mechanistically, the peptide treatment led to a 2.8-fold downregulation of LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1) expression, a key receptor for ox-LDL uptake, and a 55% inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation, a central inflammatory pathway, in aortic tissues.
Why It Matters
This research provides compelling evidence that Hexarelin possesses significant anti-atherosclerotic properties by directly interfering with a crucial mechanism of plaque formation: macrophage ox-LDL uptake. Targeting the LOX-1-NF-κB signaling pathway offers a novel therapeutic strategy for preventing or treating atherosclerosis. These findings suggest Hexarelin could be a promising candidate for drug development, warranting further preclinical studies and potentially human clinical trials for cardiovascular disease management. Future research should focus on optimizing dosing and exploring long-term safety and efficacy.